Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KITE-222 in r/r AML
NCT04789408Phase 1Terminated
- Sponsor
- Kite Pharma
- Start
- Jul 2021
- Primary completion
- May 2024
- Modality
- Bone Marrow HSCs, CAR-T Cells, Peripheral Blood HSCs
- Countries
- 2
01
Overview
Phase 1, open-label trial of KITE-222 in acute myeloid leukemia (AML) (4 arms), sponsored by Kite Pharma. Primary endpoint: Dose Limiting Toxicities at 28 days. Started Jul 2021; status: terminated.
02
Drugs
KITE-222
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT04789408.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04789408.